Moving towards differentiation TCE platform technology leader Aimai Biology updates prospectus

On December 18, Ankasa Biosciences, a pioneer in the next generation of bispecific antibody therapies, updated its prospectus to continue the process of listing on the Hong Kong Stock Exchange, with joint sponsors being CITIC SEC and CICC. The prospectus shows that Ankasa Biosciences is at the forefront of innovation in the field of bispecific antibody therapy, focusing on developing T-cell engagers (TCE) for treating various types of cancers and autoimmune diseases globally. According to the plan, the net proceeds from this IPO will mainly be used for core and key product clinical development, pipeline expansion, and operational funding, injecting strong momentum for the companys continued innovation, product advancement, and commercialization. Currently, the global market for bispecific antibody drugs is experiencing explosive growth, becoming one of the high-potential tracks in the biopharmaceutical field. According to Frost & Sullivan, the global market for bispecific drugs is projected to reach $221.8 billion by 2034, with a compound annual growth rate of 32.4% from 2024 to 2034. As an important sub-segment of the bispecific field, the TCE drug market is also rapidly expanding, growing from $400 million in 2020 to $3 billion in 2024, and is expected to reach $110.1 billion by 2034, accelerating the formation of a trillion-dollar blue ocean market. To be at the forefront of this high-growth track, Ankasa Biosciences relies on its deep technological expertise and forward-looking layout in the bispecific antibody field. As a pioneer in the next generation of bispecific antibodies, the company has established a differentiated TCE treatment with innovative foundational technology, creating an irreplicable competitive advantage. This industry confidence stems from a core leadership team with deep industry experience and a global perspective. Dr. Chenbing Wu, founder of Ankasa Biosciences, has over 20 years of biopharmaceutical experience, accumulating profound industry insights in bispecific technology innovation and product development. Dr. Yonghong Zhu, Chief Medical Officer, has extensive experience in international clinical development, translational and discovery research. The complementary strengths of core team members in their respective fields provide an important guarantee for the company's strategic implementation and technological transformation. Under the leadership of the core team, Ankasa Biosciences has built multiple proprietary technology platforms, including the FIT-Ig platform, MAT-Fab platform, and CD3 antibody library, to break through the limits of bispecific antibody development. This is the key to continuously producing innovative results and maintaining a differentiated advantage. Leveraging advanced technology platforms, Ankasa Biosciences has established a pipeline of 7 products covering oncology and immunology, including the core product EMB-01 for treating colorectal cancer, the key product EMB-06 for treating multiple myeloma, and the key product EMB-07 for treating lymphoma and solid tumors. FIT-Ig is the only bispecific technology platform in the world that does not require any amino acid mutations, connection peptide chains, or any non-antibody sequences. Clinically validated projects under research include EMB-01 and EMB-06. EMB-01, which has entered phase II trials for the treatment of colorectal cancer, is an EGFR/cMET bispecific antibody and is expected to be one of the first drugs to be marketed in this area, demonstrating Ankasa Biosciences' ability to translate platform innovation into a leading clinical position. As a complement to the FIT-Ig platform, Ankasa Biosciences has also developed the MAT-Fab platform, a proprietary bivalent alternative form that enhances the affinity for tumor-related antigens while minimizing off-target binding, particularly suitable for targets that require control of affinity. The company has already advanced EMB-07 to the clinical stage. For TCE, one of the main technical barriers is identifying the best CD3 binding agent, which requires a delicate balance between affinity and specificity to effectively reduce the risk of cytokine release syndrome. Ankasa Biosciences' CD3 antibody library platform technology customizes the design of TCE by adjusting affinity and valency, achieving optimized efficacy and safety. The dual advantage of technology platforms and product pipelines has gained high recognition from global partners. Since the end of 2023, Ankasa Biosciences has successfully reached multiple out-licensing agreements, with a cumulative transaction value exceeding $2.1 billion, ranking second globally in the TCE field. These collaborations not only validate the company's international competitiveness in innovative research and development, but also pave the way for the global promotion and commercialization of future products, accelerating the advancement of Chinese innovative drugs to the world. Standing at the forefront of the rapid development of the global bispecific and TCE treatment track, Ankasa Biosciences, with its leading advantage in proprietary innovation in bispecific platforms and product pipelines, is accelerating the construction of solid market competitive barriers. With a future listing on the Hong Kong Stock Exchange, the company is expected to enter a new development stage driven by innovation, continuously leading the innovation frontier of TCE bispecific therapy in China and globally.